SCHEMBL3534832

SCHEMBL3534832

Nc1ncc(-c2ccccn2)c2scc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.66
KDR P35968 15/20 0.63
AURKB Q96GD4 10/20 0.63
PLK4 O00444 5/20 0.63
AURKA O14965 5/20 0.63
ABL1 P00519 5/20 0.63
NTRK1 P04629 5/20 0.63
LCK P06239 5/20 0.63
FYN P06241 5/20 0.63
CSF1R P07333 5/20 0.63
LYN P07948 5/20 0.63
MET P08581 5/20 0.63
FGFR1 P11362 5/20 0.63
FLT1 P17948 5/20 0.63
FLT3 P36888 5/20 0.63
BLK P51451 5/20 0.63
NEK2 P51955 5/20 0.63
LIMK1 P53667 5/20 0.63
STK3 Q13188 5/20 0.63
ROCK1 Q13464 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526961 0.90 BRAF (0.78) BRAFKDRAURKBPLK4AURKA
SCHEMBL3567361 0.89 KDR (0.81) BRAFKDRAURKBPLK4AURKA
SCHEMBL3534924 0.87 BRAF (0.69) BRAFKDRAURKBPLK4AURKA
SCHEMBL3527384 0.87 KDR (0.76) BRAFKDRAURKBPLK4AURKA
SCHEMBL3529334 0.87 KDR (0.82) KDRAURKBPLK4AURKAABL1
SCHEMBL3527967 0.86 KDR (0.77) BRAFKDRAURKBPLK4AURKA
SCHEMBL3529474 0.85 KDR (0.80) BRAFKDRAURKBPLK4AURKA
SCHEMBL1381926 0.84 KDR (0.66) BRAFKDRAURKBPLK4AURKA
SCHEMBL3531841 0.84 KDR (0.65) BRAFKDRAURKBPLK4AURKA
SCHEMBL3530756 0.82 KDR (0.65) BRAFKDRAURKBPLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK BRAF 26/4885KDR 494/4885AURKB 171/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK BRAF 26/4885KDR 494/4885AURKB 171/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK BRAF 26/4885KDR 494/4885AURKB 171/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK BRAF 26/4885KDR 494/4885AURKB 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.